T-CURX
T-CURX is a German clinical-stage biotech developing non-viral CAR-T cell therapies for hematological malignancies and solid tumors, using proprietary Sleeping Beauty transposon technology and T-cell targeted LNP delivery to enable lower-cost bedside and in vivo CAR-T manufacturing.
- Company typePrivate
- Founded2017
- HeadquartersWürzburg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What T-CURX does
T-CURX GmbH is a privately held, venture-backed clinical-stage German biotechnology company headquartered in Würzburg with additional labs in Munich (Martinsried) and operations in Hennigsdorf and Berlin following the 2026 acquisition of Pantherna Therapeutics. The company was spun out of the University of Würzburg in March 2017 based on the academic research of co-founder Prof. Michael Hudecek and is led by CEO Ulf Grawunder, a serial biotech entrepreneur with prior exits to Agenus and Boehringer Ingelheim.
T-CURX is developing non-viral CAR-T cell therapies for cancer, built on a proprietary platform that combines Sleeping Beauty transposon gene transfer with T-cell targeted lipid-nanoparticle (LNP) delivery. This architecture is intended to eliminate the need for viral vectors, enable stable CAR expression in vivo (versus transient mRNA approaches), and support both bedside manufacturing and in vivo CAR-T generation at significantly lower cost than conventional lentivirus-based CAR-T. The lead program, TCX-001, targets Siglec-6, a target expressed on AML blasts and leukemic stem cells but not on healthy hematopoietic stem cells, enabling potential stand-alone AML therapy. TCX-001 received Swissmedic approval for a First-in-Human Phase 1 trial in relapsed/refractory AML and CLL in June 2026, and the pipeline includes three additional CAR-T programs, including two targeting novel cross-entity antigens in hematological and solid tumors.
The business model is B2B enterprise sales targeting academic medical centers, university hospitals, and clinical trial sites, with revenue expected to come from future CAR-T product sales, supplemented by licensing royalties on the 8 patent families exclusively licensed from the University of Würzburg (expanding to 16 families post-Pantherna). The company has built a commercial and clinical infrastructure spanning direct sales via business development outreach, conference-based partnering (EHA/EBMT CAR-T, BIO-Europe, BioEquity, PEGS), GMP manufacturing through the German Red Cross Frankfurt and a joint Center of Excellence with Kytopen and Fraunhofer IZI, and strategic MoUs for geographic expansion into the Middle East via FSG-Lab Dubai.
T-CURX firmographics
Firmographics- Name
- T-CURX
- Legal name
- T-CURX GmbH
- Website
- https://t-curx.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- T-CURX is a German clinical-stage biotech developing non-viral CAR-T cell therapies for hematological malignancies and solid tumors, using proprietary Sleeping Beauty transposon technology and T-cell targeted LNP delivery to enable lower-cost bedside and in vivo CAR-T manufacturing.
- Ownership category
- akta.pro rank
T-CURX industry classification
Industry- Product category
- Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
Keywords
Where T-CURX is headquartered
LocationHeadquarters
- HQ city
- Würzburg
- HQ country
- Germany
- HQ region
- Europe
Offices4 records
Markets served
T-CURX business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- CAR-T Cell Therapy Products: T-CURX develops and commercializes non-viral CAR-T cell therapies for cancer treatment. Revenue will be generated through product sales upon regulatory approval. The company is currently in clinical stage with TCX-001 in Phase 1 trials for AML and CLL.
- Licensing and IP Royalties: T-CURX holds exclusive licenses for CAR-T technologies from University of Würzburg (8 patent families) and may out-license certain technologies or receive royalties from partnered development programs.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels4 records
T-CURX product offering
Product offeringCore offering
T-CURX is a clinical-stage German biotech company that develops non-viral CAR-T cell therapies for cancer using proprietary Sleeping Beauty transposon gene-transfer technology combined with T-cell targeted lipo-nano-particle (LNP) delivery. The company is advancing a pipeline of CAR-T programs, with lead candidate TCX-001 (Siglec-6 CAR-T) in Phase 1 clinical trials for relapsed/refractory acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), alongside additional follow-on programs targeting novel cross-entity antigens expressed in hematological malignancies and solid tumors.
Differentiator
Problem solved
Functional benefit
Products and services
- TCX-001 (Siglec-6 CAR-T) Lead clinical-stage CAR-T cell therapy product developed by T-CURX for the treatment of patients with relapsed/refractory acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). TCX-001 targets Siglec-6, a differentiated antigen expressed on AML blasts and leukemic stem cells but not on healthy hematopoietic stem or progenitor cells, enabling potential stand-alone AML therapy rather than bridge-to-transplant. The product uses T-CURX's proprietary non-viral Sleeping Beauty transposon gene-transfer technology.
Quantifiable outcome
- Siglec-6 is not expressed on healthy hematopoietic stem or progenitor cells, potentially allowing AML treatment as stand-alone therapy
- +2 more outcomes
Companies that use T-CURX
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
T-CURX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
T-CURX partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- Pantherna TherapeuticscoreT-CURX acquired Pantherna Therapeutics to leverage complementary LNP-based mRNA and DNA vector delivery technologies. Pantherna operates as wholly-owned subsidiary in Hennilsdorf and Berlin. Accelerates clinical translation of in vivo CAR-T strategies with PTXmRNA and PTXDeltaLNP platforms.
- KytopencorePartnership with Kytopen Corp for Flowfect Tx non-viral continuous-flow transfection technology. Combined with T-CURX's transposon gene transfer system through Center of Excellence with Fraunhofer IZI. Technology enables scalable GMP manufacturing of engineered cells.
- Fraunhofer IZIcoreJoint Center of Excellence established with Kytopen and T-CURX for advanced non-viral cell therapy development and manufacturing scale-up. Fraunhofer IZI leads process development and manufacturing in Germany. Prof. Michael Hudecek heads Cellular Immunotherapy Branch at Fraunhofer IZI.
- FSG-Lab (First Stem Cell and Genomics Laboratory)minorMoU signed for strategic partnership to bring T-CURX non-viral CAR-T therapies to Dubai and Middle East region.
- University of WürzburgcoreT-CURX was spun out from University of Würzburg laboratory of Prof. Michael Hudecek. Exclusive license for 8 patent families covering CAR-T technologies. University Hospital Würzburg is primary clinical trial site for CAR-T programs.
- Kytopen (Technology Access)coreTechnology Access Agreement providing T-CURX access to Flowfect Tx cellular engineering platform for GMP manufacturing. First TAP partner in Europe. Kytopen installed Flowfect Tx platform on-site with dedicated Field Applications Team support.
- German Red Cross Blood Donation Center FrankfurtcoreGMP-certified manufacturing site for TCX-001 CAR-T product for clinical trials.
- CARAMBA Consortiumcore€6.1M Horizon 2020 grant consortium of 11 European partners from 6 countries developing SLAM-F7/CS1 CAR-T product using Sleeping Beauty transposon technology. T-CURX is SME partner responsible for commercial translation. 5-year grant ran 2018-2022.
- imSAVAR Consortiumminor€11M EU IMI grant with 26 partners developing integrated non-clinical assessments platform for immune safety. T-CURX participates as SME partner.
- T2EVOLVE Consortiumminor€9.5M EU IMI grant with 27 partners establishing standards for pre-clinical development, manufacturing and clinical use of CAR-T and TCR-T immunotherapies. T-CURX is SME partner.
- SaxoCell ConsortiumminorBMBF-funded Precision Therapy Cluster for Saxony focused on genetically modified CAR-T cells using Sleeping Beauty technology. T-CURX is associated SME partner.
- IMAGINE Projectminor€11.6M BMBF-funded project with 7 German partners developing super-resolution microscopy for tumor diagnostics and CAR-T eligibility assessment.
- SwissmediccoreSwiss regulatory agency that approved T-CURX's TCX-001 for First-in-Human Phase 1 clinical trial in patients with relapsed/refractory AML and CLL.
- European Medicines Agency (EMA)coreCTIS application filed with EMA to extend SIGBLAST1 trial to four clinical trial sites in Germany.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
T-CURX competitors and assessment
Company assessmentDirect peers
- Cellectis: Cellectis is a European clinical-stage biotech developing allogeneic CAR-T using TALEN gene editing. Direct competitor in the next-generation CAR-T space, with similar European footprint and clinical-stage positioning.
- Celyad Oncology: Belgian clinical-stage CAR-T developer focused on hematologic malignancies and solid tumors using NKG2D-based approaches. Comparable European clinical-stage CAR-T peer targeting similar indications including AML.
- Poseida Therapeutics: Poseida develops CAR-T therapies using a non-viral piggyBac transposon system, sharing T-CURX's core philosophy of avoiding lentiviral vectors. Both companies compete on cost-efficient, scalable CAR-T manufacturing with similar target disease areas.
- Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies using CRISPR-based gene editing. Comparable clinical-stage cell therapy company with novel gene engineering approaches to address cost and scalability challenges.
- Ziopharm Oncology: Ziopharm (now transitioning under Alaunos) was the most direct competitor using Sleeping Beauty transposon technology for non-viral CAR-T manufacturing, targeting similar hematologic malignancies. Highly comparable technology platform and clinical positioning to T-CURX.
Broad incumbents
- Novartis: Novartis commercializes Kymriah, the first FDA-approved CAR-T therapy, and has established manufacturing, payer access, and clinical infrastructure for CAR-T. Represents the dominant incumbent benchmark for CAR-T commercialization.
- Bristol Myers Squibb: BMS commercializes Breyanzi (CD19 CAR-T) and Abecma (BCMA CAR-T), with multiple clinical-stage CAR-T programs. Major incumbent in hematologic CAR-T directly competing in T-CURX's target indications.
- Gilead Sciences (Kite): Gilead's Kite Pharma division commercializes Yescarta and Tecartus, leading CAR-T products in lymphoma. Major incumbent with established autologous CAR-T manufacturing scale that T-CURX must compete against.
Emerging players
- Allogene Therapeutics: Allogene is a leading allogeneic CAR-T developer with multiple clinical programs in lymphoma and multiple myeloma. Comparable CAR-T pipeline breadth and clinical-stage maturity, though targeting different modality (allogeneic vs T-CURX's autologous).
- Eureka Therapeutics: Eureka develops CAR-T therapies with focus on solid tumors using novel antibody-engineering approaches. Comparable target profile and indication overlap with T-CURX's solid tumor pipeline programs.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
T-CURX social profiles
Digital presenceT-CURX financial estimates
Financial estimateRevenue estimate
Valuation estimate
T-CURX leadership team
Management profileNumber of profiles
Profiles12 records
T-CURX subsidiaries and ownership
Company hierarchySubsidiaries1 record
T-CURX funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
T-CURX M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about T-CURX
What does T-CURX do?
T-CURX is a clinical-stage German biotech company that develops non-viral CAR-T cell therapies for cancer using proprietary Sleeping Beauty transposon gene-transfer technology combined with T-cell targeted lipo-nano-particle (LNP) delivery. The company is advancing a pipeline of CAR-T programs, with lead candidate TCX-001 (Siglec-6 CAR-T) in Phase 1 clinical trials for relapsed/refractory acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), alongside additional follow-on programs targeting novel cross-entity antigens expressed in hematological malignancies and solid tumors.
Is T-CURX a public or private company?
T-CURX is a private company. It is classified as venture growth investor backed and is currently operating.
When was T-CURX founded?
T-CURX was founded in 2017. It employs 11 to 50 people.
Where is T-CURX based?
T-CURX is headquartered in Würzburg, Germany, in the Europe region.
How does T-CURX make money?
Two revenue lines are on record. CAR-T Cell Therapy Products are the primary driver. The others are licensing and IP Royalties.
Who are T-CURX's main competitors?
Direct peers on record are Cellectis, Celyad Oncology, Poseida Therapeutics, Caribou Biosciences and Ziopharm Oncology. Broad incumbents are Novartis, Bristol Myers Squibb and Gilead Sciences (Kite). Emerging players are Allogene Therapeutics and Eureka Therapeutics.
Does T-CURX have an API?
No public API is recorded for T-CURX.
What industry is T-CURX in?
T-CURX's product category is Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.